Antibiotic Therapy for Patients with MRSA, Streptococcus pneumoniae, and RSV

Introduction to Antibiotic Recommendations

The Infectious Diseases Society of America recommends vancomycin or linezolid as first-line agents for MRSA coverage in hospital-acquired pneumonia, with vancomycin dosing targeting trough levels of 15-20 mg/mL 1, 2
For patients with positive MRSA PCR, Streptococcus pneumoniae antigen, and RSV, dual therapy with vancomycin 15 mg/kg IV q8-12h or linezolid 600 mg IV q12h PLUS an antipseudomonal beta-lactam such as cefepime 2g IV q8h or piperacillin-tazobactam 4.5g IV q6h is recommended 1, 2

The positive MRSA PCR is a clear indication for empiric anti-MRSA therapy, as prior MRSA detection by culture or non-culture screening increases the risk of active MRSA infection 1, 3
Cefepime 2g IV q8h or piperacillin-tazobactam 4.5g IV q6h provides excellent coverage for both S. pneumoniae and potential gram-negative co-pathogens 1, 2, 3

For standard risk patients, vancomycin 15 mg/kg IV q8-12h (or linezolid 600 mg IV q12h) PLUS cefepime 2g IV q8h or piperacillin-tazobactam 4.5g IV q6h is recommended 1, 2, 3
For high-risk patients, vancomycin 15 mg/kg IV q8-12h (with loading dose 25-30 mg/kg × 1) PLUS two antipseudomonal agents from different classes, such as cefepime 2g IV q8h PLUS levofloxacin 750 mg IV daily, is recommended 1, 2, 3

Do not omit MRSA coverage when MRSA PCR is positive, as this represents a documented risk factor for active MRSA infection 1, 2
Monitor vancomycin trough levels closely to ensure therapeutic targets of 15-20 mg/mL are achieved while avoiding nephrotoxicity 1, 3

Plan for 7-10 days of total antibiotic therapy for pneumonia, adjusting based on clinical response 4
Once culture and susceptibility results are available, narrow therapy to the most appropriate targeted agent 1, 2